Evidence map›Paper›PMID 41296033›Full record

Trial reportNaunyn-Schmiedeberg's archives of pharmacology2026

Pharmacokinetics and safety evaluation of indobufen tablets under fasting and fed conditions in healthy Chinese volunteers.

Xiaoyu Lu, Hao Jiang, Mengdie Cao, Juan Li, Yanxia Yu

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaoyu LuPhase I Clinical Research Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, 215000, Jiangsu, China.
Hao JiangClinical Operations Department, Zhejiang Meidishen Biomedicine Co., Ltd, Hangzhou, 310000, Zhejiang, China.
Mengdie CaoPhase I Clinical Research Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, 215000, Jiangsu, China.
Juan LiPhase I Clinical Research Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, 215000, Jiangsu, China.
Yanxia YuPhase I Clinical Research Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, 215000, Jiangsu, China. slyyzky@163.com.

Funding

Nanjing Medical University Science Foundation NMUB20230225Suzhou Applied Basic Research and Technology Innovation Project SYWD2024132
6 · The paper itself

Abstract

To compare the pharmacokinetics and safety of indobufen (IDB) tablets and IBUSTRIN®, a randomized, open-label, two-period, two-sequence, single-dose, crossover bioequivalence study was conducted under fasting and fed conditions. A total of 48 eligible subjects were enrolled and randomly assigned to the fasting and fed groups. For each treatment period, participants received a single oral dose of 0.2 g test formulation or reference formulation. Meanwhile, blood samples were continuously collected from the subjects within 36 h after administration, and the safety was monitored throughout the study. The main pharmacokinetic parameters, such as C

Indexed as

FastingAdministration, OralAdultArea Under CurveCross-Over StudiesEast Asian PeopleFemaleFood-Drug InteractionsHealthy VolunteersHumansMaleTabletsTherapeutic EquivalencyYoung AdultTabletsBioequivalenceIndobufenPharmacokineticsSafety

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.